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Abstract
Objective
The effect of antibiotics on survival in patients with pulmonary Pseudomonas aeruginosa is
controversial. The aim of this study is to i) determine the prevalence of adequate antibiotic
treatment of P. aeruginosa in an unselected group of adult non-cystic fibrosis patients and ii)
to assess the overall mortality in study patients treated with adequate vs. non-adequate
antibiotics.
Methods
Prospective, observational study of all adult patients with culture verified P. aeruginosa from
1 January 2010–31 December 2012 in Region Zealand, Denmark. Patients with cystic fibro-
sis were excluded. Adequate therapy was defined as any antibiotic treatment including at
least one antipseudomonal beta-lactam for a duration of at least 10 days. Furthermore, P.
aeruginosa had to be tested susceptible to the given antipseudomonal drug and treatment
had to be approved by senior clinician to fulfil the adequate-criteria.
Results
A total of 250 patients were identified with pulmonary P. aeruginosa. The vast majority
(80%) were treated with non-adequate antibiotic therapy. All-cause mortality rate after 12
months was 49% in adequate treatment group vs. 52% in non-adequate treatment group.
Cox regression analysis adjusted for age, gender, bacteraemia, comorbidities and bronchi-
ectasis showed no significant difference in mortality between treatment groups (adequate
vs. non-adequate: hazard ratio 0.95, 95% CI 0.59–1.52, P = 0.82).
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Conclusion
Adequate antipseudomonal therapy was only provided in a minority of patients with pulmo-
nary P. aeruginosa. Adequate therapy did not independently predict a favourable outcome.
New research initiatives are needed to improve the prognosis of this vulnerable group of
patients.
Introduction
Pseudomonas aeruginosa is a non-fermentative Gram-negative bacillus frequently found in the
airways in hospitalised patients with underlying chronic pulmonary disease [1,2].
Infection with P. aeruginosa plays a particular important role in cystic fibrosis (CF), where
most patients acquire a chronic infection, which is associated with high morbidity and mortal-
ity [3].
While early antibiotic treatment directed against P. aeruginosa in CF has considerably
improved the clinical condition and delaying onset chronic infection, the role of antibiotics
against P. aeruginosa in other chronic pulmonary disease, as bronchiectasis or chronic
obstructive pulmonary disease (COPD), is less clear [4–6]. Present guidelines of acute and
chronic pulmonary infections with P. aeruginosa rest on low grade evidence due to lack of ran-
domised interventional trials. Instead, most treatment recommendations are based on expert
consensus and extrapolated from experience in CF [7,8].
European [9] and North American [10,11] guidelines for management of community and
hospital acquired pneumonia advocate therapeutic selection based upon severity of infection
and comorbid conditions, with an antipseudomonal beta-lactam drug as mono therapeutic
cornerstone agent. In Denmark, a common and pragmatic treatment approach to P. aerugi-
nosa infection is often intravenous antipseudomonal beta-lactam in combination with an
adjunct antibiotic for 10–14 days.
The aim of this study is to estimate the number of adult non-CF patients treated for at least
10 days beta-lactam therapy against pulmonary P. aeruginosa, and to test the hypotheses that
this regimen reduces mortality compared to patients treated with shorter treatment duration
or other use of an antibiotic agent not active against P. aeruginosa.
Materials and methods
Observational cohort study of all consecutive adult hospitalised patients with culture verified
P. aeruginosa in lower respiratory tract specimens from 1 January 2010–31 December 2012 at
the Department of Clinical Microbiology, Region Zealand, Denmark. Follow-up ended 31
December 2016. Patients below 18 years of age and patients with CF were excluded. Medical
records were reviewed for patient data: demographics, comorbidities, current medication, bac-
teraemia and blood test markers (CRP and urea). Analyses were performed on data regarding
the initial P. aeruginosa-positive sample in the study period.
For this study, the authors were granted access to microbiological data and clinical data in
medical records in accordance with current Danish laws (Data Protection Agency: REG-14-
2013). According to these, no informed patient consent or approval by The National Commit-
tee on Health Research Ethics is required.
Patients were categorised into two groups, depending on received antibiotic treatment:
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1) Adequate treatment: defined as any antibiotic therapy including at least one antipseudo-
monal beta-lactam (e.g. piperacillin/tazobactam, ceftazidime or meropenem) for a minimum
of 10 days and within 30 days after positive P. aeruginosa-sample. The following standard
doses were considered adequate based on the national recommendation at the time for the
present study: Piperacillin/tazobactam 4/0.5 every 8 hours, Ceftazidime 1 gram every 8 hours,
Meropenem 2 gram every 8 hours. Furthermore, P. aeruginosa had to be tested susceptible to
the given antipseudomonal drug and treatment had to be approved by senior clinician to fulfil
the adequate-criteria. No further requirements or evaluation of the specific drug dosages were
made by the study group.
2) Non-adequate treatment: defined as all other antibiotic treatment regimens, including
no treatment.
Outcomes
The primary outcome measure was all-cause mortality within 12 months. Secondary outcomes
measure consisted of i) recurrence of P. aeruginosa during follow-up (microbiological failure)
ii) length of first hospital stay (days). Post-hoc analyses were performed in a subgroup of
patients treated for� 14 days with dual antipseudomonal antibiotics, including at least one
beta-lactam (e.g. piperacillin/tazobactam, ceftazidime or meropenem), and compared to all
other treatment regimens.
Statistical analyses
We used a Cox regression analysis of time to death and estimated hazards ratios and corre-
sponding confidence intervals. Age, gender, bacteraemia, comorbidity (Charlson’s index of
comorbidity) and bronchiectasis were included as covariates. Continuous data were analysed
using median with corresponding interquartile range (ICR) and compared using two-sided
non-parametric test (Mann-Whitney U test). Categorical data were analysed using frequency
and percentage and compared between groups using two-sided Fischer’s exact test. P-
values< 0.05 were considered significant. All analyses were performed using SAS v. 9.4 (SAS
Institute Inc., Cary, NC, USA) and SPSS v. 22 (IBM SPSS Statistics).
Results
A total of 253 patients were detected with culture verified P. aeruginosa. Two patients were
excluded due to age below18 years and 1 patient was excluded due to known diagnosis of CF.
The remaining 250 patients were diagnosed either by sputum sampling (66%), tracheal suction
(26%) or bronchoalveolar lavage (8%). The majority of patients treated with adequate or non-
adequate antibiotics were hospitalised (86% vs. 89%) and treated under the clinical picture of
pneumonia (68% vs. 64%). Patient characteristics according to treatment group are summa-
rised in Table 1.
Treatment
Adequate treatment with antipseudomonal beta-lactam was provided in 45/250 (18%) patients
with median treatment duration of 13 days (IQR 12–14). In 40/45 (89%) patients the beta-lac-
tam treatment was supplemented with an adjunct antibiotic of either ciprofloxacin (36/40
(90%) patients) or aminoglycoside (4/40 (10%) patients). The median duration of ciprofloxa-
cin was 13 days (interquartile range (IQR) 8–15). Adequate treatment was initiated within a
median of 1 day after a positive P. aeruginosa sample (IQR 0–5).
Pseudomonas aeruginosa treatment and death
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In the non-adequate treatment group, 21/205 (10%) patients received beta-lactams as
monotherapy for a median of 3 days (IQR 2–5). In total, 33/205 (16%) patients were treated
with a combination of beta-lactam and ciprofloxacin for a median duration of 5 (IQR 3–7)
respectively 7 days (IQR 4–14). Nineteen percent (38 patients) received ciprofloxacin as mono-
therapy with a median treatment period of 9 days (IQR 5–10). The remaining 113/205 (55%)
patients did either not receive antibiotics or were treated with antibiotics lacking P. aerugi-
nosa-activity.
Outcomes
The primary outcome, all-cause mortality after 12 months, was high and similar in both the
adequate and non-adequate group (49% vs. 52%). Fig 1 illustrates Kaplan-Meier survival plot.
No significant difference was observed between the groups in the unadjusted or multivari-
able adjusted Cox regression analyses (Table 2).
Fig 2 shows the cumulative hazard for outcome.
Increasing age, bacteraemia and higher comorbidity score were independently associated
with mortality. The mortality rates were compared to a large reference population of 1.897 P.
aeruginosa-negative patients hospitalised for exacerbation of COPD and there was markedly
lower overall mortality in the reference group (30% vs. 51%). Patient characteristics are shown
in S1 Table.
The length of hospital stay was significantly longer for patients treated adequately compared
non-adequately treated (18 vs. 5 median days, IQR 3–24 vs. 2–11; p< 0.0001). Moreover, the
incidence of recurrent P. aeruginosa-positive sputum culture within the study period was not
lower in the adequate treatment group (42% vs. 32%; p = 0.22).
Post-hoc analyses
A total of 13/250 (5%) patients were treated with dual antipseudomonal antibiotics for a mini-
mum of 14 days. The mortality rate after 12 months was 15% (2/13 patients) vs. 53% (126/237
patients); Fig 3 illustrates Kaplan-Meier survival plot.
Table 1. Patient characteristics of the study cohort.
All patients Patients treated with adequate antibiotic therapy Patients treated with non-adequate antibiotic therapy
(N = 250) (N = 45) (N = 205)
Age, years, median (IQR) 71 (63–79) 72 (63–77) 71 (65–79)
Male, gender, n (%) 135 (54%) 24 (53%) 91 (44%)
Airway disease, n (%)
Asthma 14 (6%) 2 (4%) 12 (6%)
Bronchiectasis 28 (11%) 8 (18%) 20 (10%)
COPD 136 (54%) 24 (53%) 112 (55%)
Cancer, all cause, n (%) 16 (6%) 2 (4%) 14 (7%)
CCI, median (IQR) 2 (1–3) 2 (1–3) 2 (1–3)
Inhaled corticosteroid, n (%) 153 (61%) 30 (67%) 123 (60%)
Bacteraemia, n (%) 18 (7%) 3 (7%) 15 (7%)
Blood marker, median (IQR)
CRP (mg/L) 122 (47–231) 167 (57–275) 115 (47–219)
Urea (mmol/L) 6.8 (3.3–12.3) 7.1 (5.1–11.1) 6.7 (2.7–12.6)
Abbreviations: IQR, interquartile range; COPD, chronic obstructive pulmonary disease; CCI, charlson’s index of comorbidity, CPR; C-reactive protein.
https://doi.org/10.1371/journal.pone.0226935.t001
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No association was seen between dual therapy and reduced mortality when adjusting for
covariates in the Cox regression analysis (Table 3). Age, bacteraemia and comorbidity
remained as significant predictors of outcome.
Discussion
In a sample of 250 adult non-CF patients with P. aeruginosa lung infection, adequate antipseu-
domonal therapy was only provided for a minority of the patients and was not associated with
lower mortality compared to non-adequate therapy.
Our study reports markedly higher mortality rate, independent of treatment group, com-
pared to previous literature in the respiratory field [12–15]. An explanation could be inclusion
Fig 1. Unadjusted Kaplan-Meier survival estimates by treatment group in patients with pulmonary Pseudomonas aeruginosa. Red line: adequate antibiotic
treatment. Blue line: non-adequate antibiotic treatment. Log-rank test: p = 0.41.
https://doi.org/10.1371/journal.pone.0226935.g001
Table 2. Association between antibiotic treatment and all-cause mortality in cox regression model.
Unadjusted model Multivariate adjusted model
All-cause mortality after 12 months Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Adequate antibiotic treatment vs. non-adequate antibiotic treatment 0.83 (0.52–1.31) 0.42 0.95 (0.59–1.52) 0.82
Multivariate model was adjusted for age, bacteraemia, bronchiectasis, charlson’s index of comorbidity index and gender.
https://doi.org/10.1371/journal.pone.0226935.t002
Pseudomonas aeruginosa treatment and death
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of patients with bronchiectasis and more severe stage of COPD, which is closely related to
presence of pulmonary P. aeruginosa [16,17] and increased risk of mortality [18,19]. However,
the overall mortality rate was higher when compared to a large cohort of patients hospitalised
with COPD exacerbation (S1 Table). Information regarding severity of pulmonary comorbidi-
ties, including lung function test and chest computed tomography (CT), would be helpful to
explore this possible scenario in the study population. Influence by multidrug resistant P. aeru-
ginosa, which also has been related to poor prognosis [15], cannot be ruled out. However, the
overall incidence of such P. aeruginosa is low in Denmark, why any substantial influence must
be considered highly unlikely (S2 Table).
Few well-controlled studies have evaluated the optimal antibiotic treatment of P. aeruginosa
in adult non-CF patients, both inside and outside of the hospital, and the potential clinical
advantages of different treatment regimens has been a controversial subject for many years
[20–24]. To our knowledge, there are no present data making direct comparisons between
shorter or longer treatment durations and clinical outcome in patients with bronchiectasis or
COPD. General recommendations for acute infectious exacerbations (any bacterial pathogen)
are usually 5–14 days [7,25].
Fig 2. Adjusted cumulative hazard plot by treatment group in patients with pulmonary Pseudomonas aeruginosa. Green line: adequate antibiotic
treatment. Blue line: non-adequate antibiotic treatment.
https://doi.org/10.1371/journal.pone.0226935.g002
Pseudomonas aeruginosa treatment and death
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In Denmark, P. aeruginosa infection in bronchiectasis and COPD patients are typically
treated with a 10–14 days’ course of antibiotics including a pseudomonas-active beta-lactam.
Based on this, a lower limit of 10 days was set as minimum criteria for the duration of beta-lac-
tam in the present study. The median duration of 13 days of beta-lactam thus corresponds well
with the current standard of duration.
The potential clinical benefit of combination therapy over monotherapy for P. aeruginosa
has also been a subject of discussion over the last decades. Commonly cited reasons in favour
of combination therapy is the possibility of minimising the development of resistant bacterial
strains and increasing the likelihood of therapeutic success through antimicrobial synergy.
Although the Kaplan-Meier plot (Fig 2) was somewhat indicative of a difference, a
Fig 3. Unadjusted Kaplan-Meier survival estimates by treatment group in patients with pulmonary Pseudomonas aeruginosa. Red line:� 14-days dual antibiotic
treatment. Blue line: all other antibiotic treatment regimes. Log-rank test: p = 0.016.
https://doi.org/10.1371/journal.pone.0226935.g003
Table 3. Association between antibiotic treatment and all-cause mortality in post-hoc cox regression model.
Unadjusted model Multivariate adjusted model
All-cause mortality after 12 months Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
� 14-days dual antibiotic treatment vs. all other antibiotic treatment regimes. 0.21 (0.053–0.86) 0.03 0.34 (0.083–1.39) 0.13
Multivariate model was adjusted for age, bacteraemia, bronchiectasis, charlson’s index of comorbidity index and gender.
https://doi.org/10.1371/journal.pone.0226935.t003
Pseudomonas aeruginosa treatment and death
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multivariable confounder adjusted analysis did not support this. However, we cannot rule out
that the way we define our exposure of adequate versus non-adequate treatment regimen
could potentially bias interpretations.
Despite our interesting findings, the study also has important limitations which need to be
taken into consideration when interpreting the results. First, the study is an observational
study. Due to the non-randomised design, the results cannot determine causality between
treatment and outcome. A potential limitation is confounding by indication since treatment is
highly likely to be influenced by the severity of disease. Thus, it is possible, that the adequate
regimen is given to the patients with most severe clinical state, and less favourable prognosis,
while less sick patients, with better prognosis, could be expected to be treated less aggressively.
The adequately treated patients might therefore have worse or, at best, similar prognosis as the
non-adequately treated patients. On the contrary, a severe state might also lead to early discon-
tinuation of treatment, and thereby non-adequate duration. However, the significant longer
hospital admission among the adequately treated patients suggest that the first argument is
more likely to be the case in our study. Moreover, we have not registered the administered
antibiotic dosage on patient level. Although we expect the adequate antibiotic treatment regi-
mens to be given according to national guidelines, we cannot be completely certain of this as
the study group made no independent assessment of the drug administrations. This is a major
limitation. However, P. aeruginosa had to be tested susceptible to the given antipseudomonal
drug and treatment had to be approved by senior clinician to fulfil the adequate-criteria. Data
regarding resistance was not registered but is expected to be low based on microbiological data
from the Capital Region in Denmark (S2 Table).
Secondly, the study population is inhomogeneous. This challenges group comparisons and
makes it difficult to draw a definite conclusion based on the results. However, the sample size
in the current study is larger than in most comparable studies. Another strength is the conse-
cutive selection of patients, which reduces the risk of selection bias.
Conclusion
Adequate antipseudomonal therapy was only provided in a minority of patients with pulmo-
nary P. aeruginosa. Overall mortality rates were high in both treatment groups and adequate
therapy did not independently predict a favourable outcome. Thus, our data support the clini-
cal impression that lung infections with P. aeruginosa are complex. New research initiatives
are needed to improve the prognosis of this vulnerable group.
Supporting information
S1 Table. Patient characteristics of the study population and reference population: The
reference population consists of 1.897 P. aeruginosa-negative COPD outpatients hospital-
ised with exacerbation of COPD in Region Zealand and the Capital Region in Denmark in
2010–2012.
(DOCX)
S2 Table. Antibiotic resistance in P. aeruginosa during 2005–2013 in the Capital Region of
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